IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 01 2025
0mins
Should l Buy TNGX?
Source: NASDAQ.COM
Earnings Performance: IGM Biosciences, Inc. reported quarterly earnings of $1.58 per share, significantly exceeding expectations and showing a substantial improvement from a loss of $0.79 per share a year ago, while revenues reached $143.62 million, far surpassing estimates.
Market Outlook: Despite the positive earnings report, IGM's stock has underperformed this year, with a Zacks Rank of #5 (Strong Sell), indicating expected continued underperformance in the near future, influenced by unfavorable estimate revisions and industry trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNGX
Wall Street analysts forecast TNGX stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.320
Low
12.00
Averages
13.67
High
15.00
Current: 19.320
Low
12.00
Averages
13.67
High
15.00
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating varying perspectives on the company's future, which could influence investor decisions and market sentiment.
- Market Reaction Expectations: Although specific rating changes are not detailed in the report, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor these shifts for informed investment choices.
- Lack of Investment Advice: The report notes that Benzinga does not provide investment advice, emphasizing the importance for investors to rely on their own research and analysis rather than solely on analysts' ratings.
- Diverse Information Sources: To gain a more comprehensive view of analyst rating changes, investors are encouraged to visit Benzinga's analyst ratings page for the latest upgrades and downgrades information.
See More
Tango Therapeutics Grants Stock Options and RSUs to New Employee
- Stock Option Grant: Tango Therapeutics granted 367,500 stock options to a new employee on February 2, 2026, with an exercise price of $11.94 per share, reflecting the company's commitment to incentivizing key talent and enhancing employee retention.
- Restricted Stock Units: Additionally, 60,000 restricted stock units (RSUs) were awarded, with 20,000 shares vesting on February 1, 2027, further strengthening the long-term incentive structure and promoting employee engagement and loyalty.
- Inducement Plan Context: The grants are made under Tango Therapeutics' 2023 Inducement Plan, specifically designed to attract new employees, showcasing the company's strategic focus on talent acquisition to drive future innovation and growth.
- Long-Term Incentive Structure: The staggered vesting schedule for stock options and RSUs over the next three years ensures that employees remain committed to the company while fostering a sense of ownership and participation in the company's long-term success.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tango Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Tango Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.03, indicating some resilience in financial performance despite overall revenue shortfalls.
- Revenue Performance: The company reported $0M in revenue for Q4, missing the target by $0.5M, reflecting challenges in market penetration or product sales that could impact future cash inflows.
- Cash Reserves: As of December 31, 2025, Tango held $343.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028, showcasing solid financial management.
- Market Outlook: Despite current financial shortcomings, Tango Therapeutics is actively participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating efforts to bolster investor confidence and explore market opportunities.
See More
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating varying perspectives on the company's future, which could influence investor decisions and market sentiment.
- Market Reaction Expectations: Although specific rating changes are not detailed in the report, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor these shifts for informed investment choices.
- Lack of Investment Advice: The report notes that Benzinga does not provide investment advice, emphasizing the importance for investors to rely on their own research and analysis rather than solely on analysts' ratings.
- Diverse Information Sources: To gain a more comprehensive view of analyst rating changes, investors are encouraged to visit Benzinga's analyst ratings page for the latest upgrades and downgrades information.
See More
Tango Therapeutics Grants Stock Options and RSUs to New Employee
- Stock Option Grant: Tango Therapeutics granted 367,500 stock options to a new employee on February 2, 2026, with an exercise price of $11.94 per share, reflecting the company's commitment to incentivizing key talent and enhancing employee retention.
- Restricted Stock Units: Additionally, 60,000 restricted stock units (RSUs) were awarded, with 20,000 shares vesting on February 1, 2027, further strengthening the long-term incentive structure and promoting employee engagement and loyalty.
- Inducement Plan Context: The grants are made under Tango Therapeutics' 2023 Inducement Plan, specifically designed to attract new employees, showcasing the company's strategic focus on talent acquisition to drive future innovation and growth.
- Long-Term Incentive Structure: The staggered vesting schedule for stock options and RSUs over the next three years ensures that employees remain committed to the company while fostering a sense of ownership and participation in the company's long-term success.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tango Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Tango Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.03, indicating some resilience in financial performance despite overall revenue shortfalls.
- Revenue Performance: The company reported $0M in revenue for Q4, missing the target by $0.5M, reflecting challenges in market penetration or product sales that could impact future cash inflows.
- Cash Reserves: As of December 31, 2025, Tango held $343.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028, showcasing solid financial management.
- Market Outlook: Despite current financial shortcomings, Tango Therapeutics is actively participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating efforts to bolster investor confidence and explore market opportunities.
See More
